Sironax
Transformative therapies for degenerative diseases
- Headquarters
- Beijing
- Employees
- 51–200
- Founded
- 2017
- Business Model
- B2B
- Website
- sironax.com
- Total Funding
- $200.0M
- Last Round
- $200.0M Series BAug 2022
- Rounds
- 1
About
Sironax is a clinical-stage biotechnology company founded in 2017 by Dr. Xiaodong Wang and Dr. Zhiyuan Zhang, targeting neurodegenerative, inflammatory, metabolic, and rare diseases. The company is advancing three clinical candidates—SIR2501, SIR9900, and SIR4156—with 170+ employees across the US, China, Switzerland, and Australia. In 2025, Sironax granted Novartis an exclusive option to acquire its Brain Delivery Platform.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Aug 2022
Investors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
Biopharmaceutical services company
Specialty pharmaceutical company
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...